Haohao Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haohao Yin has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Hui-Xiong Xu
Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China
24 shared publications Shen Zhang
Department of Ultrasound Zhongshan Hospital Institute of Ultrasound in Medicine and Engineering Fudan University Shanghai People's Republic of China
10 shared publicationsYan Fang
Department of Ultrasound Huashan Hospital Fudan University Shanghai People's Republic of China
10 shared publicationsJifeng Yu
Department of Ultrasound Zhongshan Hospital Institute of Ultrasound in Medicine and Engineering Fudan University Shanghai People's Republic of China
9 shared publicationsBing Xiong
Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, PR China; Institute of Medical Ultrasound and Engineering, Fudan University, Shanghai 200032, PR China; Shanghai Institute of Medical Imaging, Shanghai 200032, PR China
7 shared publicationsMingrui Zhu
Department of Ultrasound Zhongshan Hospital Institute of Ultrasound in Medicine and Engineering Fudan University Shanghai People's Republic of China
7 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Wiley in Advanced Science
- p. e78432
Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis
The global epidemic of metabolic dysfunction‐associated steatohepatitis (MASH) is escalating without effective therapies. This study identified a significant depletion of the gut commensal bacterium Faecalibacterium duncaniae ( F. duncaniae ) as a core feature of MASH. To overcome the poor colonization by traditional probiotics in inflammatory environments, we engineered a living microbial therapeutic by incorporating chiral gold nanozymes onto F. duncaniae . We discovered that biological performance is enantiomer‐dependent: the right‐handed nanozyme (D‐Au) serves as a superior ROS‐scavenging shield, protecting the probiotic from oxidative assault and enhancing its colonization in the inflamed gut. In mouse models of MASH, this engineered probiotic (F@D‐Au) reversed disease progression, ameliorating steatosis, inflammation, and fibrosis. It further restored systemic homeostasis, rectifying dysbiosis, metabolic disturbances, and—notably—MASH‐associated cognitive impairment. Metabolomic analyses revealed that this multi‐organ benefit was linked to the restoration of key microbial metabolites, including kynurenic acid and linoleic acid. Our work establishes a new class of chirality‐enhanced living therapeutics that precisely remodel the gut–liver axis, offering a transformative strategy for treating MASH and its complications.
- 4 November 2026
- Published by Wiley in Advanced Science
- p. e78432
Open AccessEngineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis
The global epidemic of metabolic dysfunction‐associated steatohepatitis (MASH) is escalating without effective therapies. This study identified a significant depletion of the gut commensal bacterium Faecalibacterium duncaniae ( F. duncaniae ) as a core feature of MASH. To overcome the poor colonization by traditional probiotics in inflammatory environments, we engineered a living microbial therapeutic by incorporating chiral gold nanozymes onto F. duncaniae . We discovered that biological performance is enantiomer‐dependent: the right‐handed nanozyme (D‐Au) serves as a superior ROS‐scavenging shield, protecting the probiotic from oxidative assault and enhancing its colonization in the inflamed gut. In mouse models of MASH, this engineered probiotic (F@D‐Au) reversed disease progression, ameliorating steatosis, inflammation, and fibrosis. It further restored systemic homeostasis, rectifying dysbiosis, metabolic disturbances, and—notably—MASH‐associated cognitive impairment. Metabolomic analyses revealed that this multi‐organ benefit was linked to the restoration of key microbial metabolites, including kynurenic acid and linoleic acid. Our work establishes a new class of chirality‐enhanced living therapeutics that precisely remodel the gut–liver axis, offering a transformative strategy for treating MASH and its complications.
- Open Access
- 8 October 2026
- Published by Wiley in Advanced Science
- p. e78100
Sonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut‐Liver Axis
Metabolic dysfunction‐associated steatohepatitis (MASH) currently lacks effective targeted therapeutics, while interleukin‐22 (IL‐22) as a potential treatment approach faces challenges in the clinical translation due to off‐target risks associated with systemic delivery. To address this limitation, we developed an intelligent oral biologics platform centered on an engineered probiotic strain ( Escherichia coli Nissle 1917) capable of producing therapeutic IL‐22 in situ, encapsulated within an inulin hydrogel to resist gastric degradation. Critically, we integrated a sonogenetic control module that enables non‐invasive, spatiotemporally precise activation of IL‐22 expression in the gut via remote ultrasound stimulation. In MASH model, this targeted, on‐demand IL‐22 delivery effectively remodeled the gut microbiota and improved intestinal barrier function. This led to significantly reduced portal lipopolysaccharide (LPS) levels, which in turn decreased hepatic IL‐6 production. Mechanistically, this strategy inhibited the pathological overactivation of the PI3K‐AKT‐mTOR signaling pathway, thereby markedly ameliorating hepatic steatosis, inflammation, and fibrosis. Notably, by confining IL‐22 production to the gut, this strategy completely circumvented the off‐target effects of conventional IL‐22 therapy. We observed reversal of MASH‐associated cognitive impairment, highlighting systemic benefits of restoring gut‐liver axis homeostasis. This study establishes a transformative, multi‐beneficial MASH therapy paradigm by modulating the gut‐liver axis, offering a safe, effective, clinically translatable strategy.
- 8 October 2026
- Published by Wiley in Advanced Science
- p. e78100
Open AccessSonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut‐Liver Axis
Metabolic dysfunction‐associated steatohepatitis (MASH) currently lacks effective targeted therapeutics, while interleukin‐22 (IL‐22) as a potential treatment approach faces challenges in the clinical translation due to off‐target risks associated with systemic delivery. To address this limitation, we developed an intelligent oral biologics platform centered on an engineered probiotic strain ( Escherichia coli Nissle 1917) capable of producing therapeutic IL‐22 in situ, encapsulated within an inulin hydrogel to resist gastric degradation. Critically, we integrated a sonogenetic control module that enables non‐invasive, spatiotemporally precise activation of IL‐22 expression in the gut via remote ultrasound stimulation. In MASH model, this targeted, on‐demand IL‐22 delivery effectively remodeled the gut microbiota and improved intestinal barrier function. This led to significantly reduced portal lipopolysaccharide (LPS) levels, which in turn decreased hepatic IL‐6 production. Mechanistically, this strategy inhibited the pathological overactivation of the PI3K‐AKT‐mTOR signaling pathway, thereby markedly ameliorating hepatic steatosis, inflammation, and fibrosis. Notably, by confining IL‐22 production to the gut, this strategy completely circumvented the off‐target effects of conventional IL‐22 therapy. We observed reversal of MASH‐associated cognitive impairment, highlighting systemic benefits of restoring gut‐liver axis homeostasis. This study establishes a transformative, multi‐beneficial MASH therapy paradigm by modulating the gut‐liver axis, offering a safe, effective, clinically translatable strategy.
- Open Access
- 29 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (63) , e77337
Defect‐Engineered BiO 2‐X Nanosheets Mediate Sono‐Thermomechanical ECM Remodeling for Hepatocellular Carcinoma Immunotherapy
Immune checkpoint blockade for hepatocellular carcinoma (HCC) is frequently limited by the extracellular matrix (ECM). Through transcriptomic profiling, we identify that acquired anti‐PD‐1 resistance in HCC models is closely associated with prominent Fibronectin 1 (Fn1) upregulation within the tumor microenvironment. To address these interconnected physical and biological barriers, we developed an ultrasound‐responsive nanoplatform utilizing oxygen‐defect‐abundant 2D BiO 2‐X nanosheets loaded with Fn1‐targeted small interfering RNA (BiO 2‐X /siFn1). Introducing oxygen vacancies into ultrathin BiO 2‐X alters its band structure, enhancing sono‐thermomechanical energy conversion under localized acoustic excitation. This synchronized sono‐thermomechanical effect physically remodels the dense collagen matrix, enhancing intratumoral permeation and spatially facilitating immune cell infiltration without relying on extreme hyperthermia. Concurrently, sonothermal‐sonomechanical synergistic enhancement of intracellular delivery of siFn1 efficiently downregulates Fn1 expression. This genetic intervention deprives detached tumor cells of integrin‐mediated focal adhesion survival signals, resensitizing them to anoikis and effectively suppressing ECM‐associated pulmonary metastasis. The BiO 2‐X /siFn1 nanoplatform significantly increased the recruitment of CD8 + T cells in tumors and restored the therapeutic effect of inhibiting PD‐1 in HCC by combining macroscopic physical ECM remodeling with precise molecular blocking of mechanical conduction pathways. This defect‐engineered sonosensitization strategy modulates the solid tumor microenvironment and overcomes mechanically induced immunotherapy resistance.
- 29 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (63) , e77337
Open AccessDefect‐Engineered BiO 2‐X Nanosheets Mediate Sono‐Thermomechanical ECM Remodeling for Hepatocellular Carcinoma Immunotherapy
Immune checkpoint blockade for hepatocellular carcinoma (HCC) is frequently limited by the extracellular matrix (ECM). Through transcriptomic profiling, we identify that acquired anti‐PD‐1 resistance in HCC models is closely associated with prominent Fibronectin 1 (Fn1) upregulation within the tumor microenvironment. To address these interconnected physical and biological barriers, we developed an ultrasound‐responsive nanoplatform utilizing oxygen‐defect‐abundant 2D BiO 2‐X nanosheets loaded with Fn1‐targeted small interfering RNA (BiO 2‐X /siFn1). Introducing oxygen vacancies into ultrathin BiO 2‐X alters its band structure, enhancing sono‐thermomechanical energy conversion under localized acoustic excitation. This synchronized sono‐thermomechanical effect physically remodels the dense collagen matrix, enhancing intratumoral permeation and spatially facilitating immune cell infiltration without relying on extreme hyperthermia. Concurrently, sonothermal‐sonomechanical synergistic enhancement of intracellular delivery of siFn1 efficiently downregulates Fn1 expression. This genetic intervention deprives detached tumor cells of integrin‐mediated focal adhesion survival signals, resensitizing them to anoikis and effectively suppressing ECM‐associated pulmonary metastasis. The BiO 2‐X /siFn1 nanoplatform significantly increased the recruitment of CD8 + T cells in tumors and restored the therapeutic effect of inhibiting PD‐1 in HCC by combining macroscopic physical ECM remodeling with precise molecular blocking of mechanical conduction pathways. This defect‐engineered sonosensitization strategy modulates the solid tumor microenvironment and overcomes mechanically induced immunotherapy resistance.
- 18 June 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 397, 115114
Ultrasound-programmable tumor extracellular vesicles delivery system for dual immune–epigenetic therapy against colorectal cancer metastasis
- 18 June 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 397, 115114
Ultrasound-programmable tumor extracellular vesicles delivery system for dual immune–epigenetic therapy against colorectal cancer metastasis
- Open Access
- 8 April 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (5) , 102773
LIFUS-driven engineered bacteria reprogram immunosuppressive niches via mechano-NOTCH signaling
- 8 April 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (5) , 102773
Open AccessLIFUS-driven engineered bacteria reprogram immunosuppressive niches via mechano-NOTCH signaling
- Open Access
- 19 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Low-intensity focused ultrasound-activated piezoelectric gel bandage for diabetic wound repair and neuropathic pain relief
Nociceptive hypersensitivity and prolonged wound healing due to the interaction of peripheral neuropathy and local immune disorders are key issues that need to be addressed in diabetic foot ulcer (DFU) regenerative repair. Here, we present a low-intensity focused ultrasound (LIFU)-activated piezoelectric gel bandage for DFU wound repair and neuropathic pain relief. Acting as an artificial “skin”, this self-powered, functionalized bandage not only temporarily shields tissue from external environment, but also serves as a drug reservoir that can in situ release nitric oxide upon LIFU to promote macrophage polarization, generate piezoelectric current to desensitize TRPV1 nociceptor for on demand neuropathic pain relief and produce reactive oxygen species to eliminate pathogens in male rodents. More importantly, this regimen can promote CGRP neuropeptides release from sensory neurons to invigorate M2-like macrophages-mediated protective cutaneous immunity. This LIFU-activated immune-nociceptor modulation strategy is potentially applicable to other non-healing tissue regeneration.
- 19 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessLow-intensity focused ultrasound-activated piezoelectric gel bandage for diabetic wound repair and neuropathic pain relief
Nociceptive hypersensitivity and prolonged wound healing due to the interaction of peripheral neuropathy and local immune disorders are key issues that need to be addressed in diabetic foot ulcer (DFU) regenerative repair. Here, we present a low-intensity focused ultrasound (LIFU)-activated piezoelectric gel bandage for DFU wound repair and neuropathic pain relief. Acting as an artificial “skin”, this self-powered, functionalized bandage not only temporarily shields tissue from external environment, but also serves as a drug reservoir that can in situ release nitric oxide upon LIFU to promote macrophage polarization, generate piezoelectric current to desensitize TRPV1 nociceptor for on demand neuropathic pain relief and produce reactive oxygen species to eliminate pathogens in male rodents. More importantly, this regimen can promote CGRP neuropeptides release from sensory neurons to invigorate M2-like macrophages-mediated protective cutaneous immunity. This LIFU-activated immune-nociceptor modulation strategy is potentially applicable to other non-healing tissue regeneration.
- Open Access
- 9 March 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (3) , 102658
LIFUS-driven engineered bacteria reprogram immunosuppressive niches via mechano-NOTCH signaling
- 9 March 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (3) , 102658
Open AccessLIFUS-driven engineered bacteria reprogram immunosuppressive niches via mechano-NOTCH signaling
- Open Access
- 26 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Sono-triggered endoplasmic reticulum-targeted ROS burst silencing CD300ld to alleviate polymorphonuclear myeloid-derived suppressor cells for breast cancer treatment
Immunogenic cell death (ICD) significantly boosts anti-tumor immunotherapy effectiveness; however, the recruitment of polymorphonuclear myeloid-derived sup
- 26 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1)
Open AccessSono-triggered endoplasmic reticulum-targeted ROS burst silencing CD300ld to alleviate polymorphonuclear myeloid-derived suppressor cells for breast cancer treatment
Immunogenic cell death (ICD) significantly boosts anti-tumor immunotherapy effectiveness; however, the recruitment of polymorphonuclear myeloid-derived sup
- 7 November 2025
- Published by Springer Nature in European Radiology
- Vol. 36 (4) , 3192-3205
Ultrasound-based fat fraction for detection of hepatic steatosis and quantification of liver fat content using liver biopsy as the reference standard
Objectives To analyze the diagnostic performance of tissue attenuation imaging (TAI), tissue scatter-distribution imaging (TSI) and ultrasound-based fat fraction (USFF) in suspected metabolic-associated fatty liver disease (MASLD), using histopathological hepatic steatosis as the reference standard. Materials and methods This was a retrospective analysis of prospectively recruited participants with suspected MASLD from August 2022 to November 2023. TAI, TSI and USFF were measured. Spearman correlation analysis was used to evaluate the correlation of TAI, TSI and USFF with hepatic steatosis. The diagnostic performance for detecting hepatic steatosis was evaluated by multiclass or binary receiver operating characteristic (ROC) curves. Results A total of 264 participants were enrolled, including 227 with biopsy-confirmed MASLD and 37 with normal liver biopsy results. Compared with TAI and TSI, USFF had a better positive correlation with hepatic steatosis in the overall set (rUSFF = 0.62, rTAI = 0.57, rTSI = 0.56; all p < 0.001). Multiclass ROC analysis indicated TAI, TSI and USFF exhibited only modest to suboptimal diagnostic performance for all hepatic steatosis (S0-S3) in index (volume under surface (VUS) 0.21–0.51) and validation set (VUS 0.18–0.34). However, binary ROC curves revealed TAI, TSI and USFF yielded the highest AUCs in detecting mild or greater hepatic steatosis in index (AUC 0.95–0.98) and validation set (AUC 0.92–0.96). Conclusions USFF has a good correlation with histopathological hepatic steatosis grade. TAI, TSI and USFF might be potential quantitative diagnostic tools for detecting mild hepatic steatosis in MASLD, though further validation in larger and more balanced cohorts is needed. Key Points Question How is the diagnostic performance of quantitative ultrasound parameters in suspected metabolic dysfunction-associated steatotic liver disease using liver biopsy as the reference standard? Findings Tissue attenuation imaging, tissue scatter-distribution imaging and ultrasound-based fat fraction show promising diagnostic potential for mild hepatic steatosis in metabolic dysfunction-associated steatotic liver disease. Clinical relevance Tissue attenuation imaging, tissue scatter-distribution imaging, and ultrasound-based fat fraction might be potential noninvasive tools for detecting mild hepatic steatosis and conducting large-scale follow-ups in metabolic dysfunction-associated steatotic liver disease. Graphical Abstract
- 7 November 2025
- Published by Springer Nature in European Radiology
- Vol. 36 (4) , 3192-3205
Ultrasound-based fat fraction for detection of hepatic steatosis and quantification of liver fat content using liver biopsy as the reference standard
Objectives To analyze the diagnostic performance of tissue attenuation imaging (TAI), tissue scatter-distribution imaging (TSI) and ultrasound-based fat fraction (USFF) in suspected metabolic-associated fatty liver disease (MASLD), using histopathological hepatic steatosis as the reference standard. Materials and methods This was a retrospective analysis of prospectively recruited participants with suspected MASLD from August 2022 to November 2023. TAI, TSI and USFF were measured. Spearman correlation analysis was used to evaluate the correlation of TAI, TSI and USFF with hepatic steatosis. The diagnostic performance for detecting hepatic steatosis was evaluated by multiclass or binary receiver operating characteristic (ROC) curves. Results A total of 264 participants were enrolled, including 227 with biopsy-confirmed MASLD and 37 with normal liver biopsy results. Compared with TAI and TSI, USFF had a better positive correlation with hepatic steatosis in the overall set (rUSFF = 0.62, rTAI = 0.57, rTSI = 0.56; all p < 0.001). Multiclass ROC analysis indicated TAI, TSI and USFF exhibited only modest to suboptimal diagnostic performance for all hepatic steatosis (S0-S3) in index (volume under surface (VUS) 0.21–0.51) and validation set (VUS 0.18–0.34). However, binary ROC curves revealed TAI, TSI and USFF yielded the highest AUCs in detecting mild or greater hepatic steatosis in index (AUC 0.95–0.98) and validation set (AUC 0.92–0.96). Conclusions USFF has a good correlation with histopathological hepatic steatosis grade. TAI, TSI and USFF might be potential quantitative diagnostic tools for detecting mild hepatic steatosis in MASLD, though further validation in larger and more balanced cohorts is needed. Key Points Question How is the diagnostic performance of quantitative ultrasound parameters in suspected metabolic dysfunction-associated steatotic liver disease using liver biopsy as the reference standard? Findings Tissue attenuation imaging, tissue scatter-distribution imaging and ultrasound-based fat fraction show promising diagnostic potential for mild hepatic steatosis in metabolic dysfunction-associated steatotic liver disease. Clinical relevance Tissue attenuation imaging, tissue scatter-distribution imaging, and ultrasound-based fat fraction might be potential noninvasive tools for detecting mild hepatic steatosis and conducting large-scale follow-ups in metabolic dysfunction-associated steatotic liver disease. Graphical Abstract